EFFECTS OF IMMUNOMODULATORY TREATMENT WITH SUBCUTANEOUS INTERFERON BETA-1A ON COGNITIVE DECLINE IN MILDLY DISABLED PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS